Solid produces best-in-class biomarker data among DMD gene therapies

The promise that programs may offer meaningful improvements over Duchenne muscular dystrophy gene therapy Elevidys delandistrogene moxeparvovec came into greater focus this week with clinical results from Solid. 

The results led Solid Biosciences Inc. (NASDAQ:SLDB) shares to record the largest single-day gain on clinical data over the past week, followed closely by data from Anaptysbio Inc. (NASDAQ:ANAB), whose readout helps build the case for PD-1 agonism as a novel mechanism for inflammatory diseases...